HCW Biologics Stock Surges 75.41% Amid Market Volatility

Bristol-Myers Squibb Co (BMY) has seen a decline in stock price, dropping 3.56% over the past week, attributed to lowered revenue guidance and concerns over patent expirations despite beating Q4 earnings expectations. Analysts are mixed on BMY, with 4 recommending a 'buy' and 17 suggesting a 'hold,' while Jefferies has set a target price of $70. In contrast, HCW Biologics Inc (HCWB) experienced a remarkable 75.41% increase in stock price recently, following FDA approval for a clinical trial of its drug candidate HCW9302 aimed at treating alopecia areata. Microbot Medical Inc (MBOT) also saw a substantial increase of 38.59% in its stock price over the last week, with analysts giving mixed ratings, yet H.C. Wainwright has categorized it as a 'buy.' Cyclo Therapeutics Inc (CYTH) reported a 30.91% rise in stock price, driven by ongoing research developments despite previous market setbacks. Each of these companies showcases varied stock performance and analyst sentiment amid their respective market challenges.